“Fear of the unknown” limiting adoption of real-time release testing, FDA says

By Nick Taylor

- Last updated on GMT

Related tags Fda

Real-time release testing can save money by cutting recalls but “fear of the unknown” is limiting use, a FDA official said.

The US Food and Drug Administration (FDA) “encourages and supports​” real-time release testing and many larger companies possess the technical capabilities. However, adoption is limited by problems, both real and perceived.

On the perceived side, I think a lot of it is the fear of the unknown. Companies haven’t used these approaches before and they’re concerned about how they work​”, Christine Moore, acting director, office of new drug quality assessment at the FDA, told in-PharmaTechnologist.

Companies that overcome these fears will benefit. “As they have more robust processes they’re going to have less problems, less failures, recalls etc. It’s difficult to put a money figure on problems that don’t happen, but I think that’s where the real cost savings…are going to be​”, Moore said.

Related news

Show more

Related products

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Understanding the hidden value of quality

Understanding the hidden value of quality

Content provided by Thermo Fisher Scientific – Production Chemicals and Services | 16-Jan-2023 | White Paper

The raw material supply is too vital to leave to chance, and quality-related supply chain activities are cornerstones to your success.

Follow us


View more